REMARKS

Claims 55-107 are currently pending in the application. Claims 1-54 have been canceled without prejudice. Applicants reserve the right to file one or more continuation or divisional applications directed to any canceled subject matter. Claims 55-107 are therefore pending on the merits upon entry of this paper. No new matter has been added.

I. <u>Election</u>

Applicants would first like to point out that the pending claims are directed to compounds of formula III, IV, and V.

Applicants elect the compound of formula III as recited in claim 55. Applicants elect the single species encompassed by formula III with traverse, wherein:

```
R^{11} is -(CH_2)_{11}CH_3;

X^{11} is O;

X^{12} is O;

R^{12} is -(CH_2)_{11}CH_3;

X^{13} is O;

n is 0; and

R^{13} is an anticancer agent, specifically gemicitabine.
```

Applicants respectfully submit that a single search of (C_1-C_{16}) alkyl would necessarily encompass all of the species recited by R^{11} and R^{12} in claim 55. Moreover, Applicants further submit that a search of anticancer agents would necessarily encompass the anticancer agents recited by the pending claims.

Applicants respectfully submit that claims 55, 56 and 61-105 are readable on the elected species.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application, including fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including

any required extension of time, fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: June 4, 2007

Dean L. Fanelli Reg. No. 48,907

Correspondence Address: Customer Number: 09629

MORGAN, LEWIS & BOCKIUS LLP

1111 Pennsylvania Avenue, NW

Washington, DC 20004

(202) 739-3000-p (202) 739-3001-f